Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to therapy caused by intragenic deletion in BRCA2.

Nature - 28 Feb 2008

Edwards Stacey L, Brough Rachel, Lord Christopher J, Natrajan Rachael, Vatcheva Radost, Levine Douglas A, Boyd Jeff, Reis-Filho Jorge S, Ashworth Alan

Abstract excerpt

Cells with loss of BRCA2 function are defective in homologous recombination (HR) and are highly sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP), which provides the basis for a new therapeutic approach. Here we show that resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2. We derived PARP-inhibitor-resistant (PIR) clones from the human CAPAN1 pancreatic cancer cell line,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Mitomycin

Share to Open Reading Frames

Share to Pancreatic Neoplasms

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 18264088
DOI: 10.1038/nature06548

Genes

BRCA2
PIR
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to therapy caused by intragenic deletion in BRCA2.PMID 18264088Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.Semantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.Semantic proximity Read ↗

Targeting BRCA and PALB2 in Pancreatic Cancer.Semantic proximity Read ↗

An inducible BRCA1 expression system with <i>in vivo</i> applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistanceSemantic proximity Read ↗

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read ↗

Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and ChemopreventionSemantic proximity Read ↗

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.Semantic proximity Read ↗

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Semantic proximity Read ↗

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.